| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2009: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Research Abstract |
B7-H1 is a co-signal to modulate immune check point expressed on both subsets of immune effector cells and cancer. B7-H1 is able to induce an anergy of CD8+ T cells through the PD-1 receptor leading to tumor growth and immune suppression. Blockade of B7-H1 with neutralizing antibody is a novel therapy which alters tumor microenvironment. The antibody blockade of this B7-H1/ PD-1 interaction may result in the alteration of immune response and tumor microenvironment preventing tumor evasion from the immune system. Materials and Methods:
BALB/ C mice were challenged with colorectal hepatic metastases and then treated with an attenuated Listeria monocytogenes(LM) vaccine platform in combination with B7-H1 blocking antibody. Mice were investigated for survival, immunological analysis with flow cytometry and in vitro assay
Results : Mice treated with B7-H1+ LM had 70% survival. The analysis of immune subsets demonstrated an increase in expression of B7-H1 on CD8+ T cells of mice treated with LM. In vitro analysis of CD8+ T cell activation showed an increase of 50% in the presence of tumor with B7-H1 blocking antibody.
Discussion : B7-H1 blockade showed increased survival by preventing the inhibitory signaling between T cells, dendritic cells and tumor.
|
